# Ana B. Rossi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ana-b-rossi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,533 |
| Field | Dermatology and Skin Diseases |
| h-index | 26 |
| i10-index | 62 |
| Last Known Institution | Sanofi (United States) |
| OpenAlex ID | https://openalex.org/A5012209760 |
| ORCID iD | 0000-0001-5345-678X |
| Works | 176 |

## Researcher papers

- [Atopic dermatitis in the pediatric population](https://scholariq.org/papers/atopic-dermatitis-in-the-pediatric-population/)
- [Ultraviolet radiation and the skin: Photobiology and sunscreen photoprotection](https://scholariq.org/papers/ultraviolet-radiation-and-the-skin-photobiology-and-sunscreen-photoprotection/)
- [Cellulite: a review](https://scholariq.org/papers/cellulite-a-review/)
- [Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis](https://scholariq.org/papers/type-2-inflammation-contributes-to-skin-barrier-dysfunction-in-atopic-dermatitis/)
- [Influence of facial skin attributes on the perceived age of Caucasian women](https://scholariq.org/papers/influence-of-facial-skin-attributes-on-the-perceived-age-of-caucasian-women/)
- [Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)](https://scholariq.org/papers/laboratory-safety-of-dupilumab-in-moderate-to-severe-atopic-dermatitis-results/)
- [Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years](https://scholariq.org/papers/safety-and-tolerability-of-1-pimecrolimus-cream-among-infants-experience-with/)
- [Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS](https://scholariq.org/papers/dupilumab-treatment-results-in-early-and-sustained-improvements-in-itch-in/)
- [Nomenclature and clinical phenotypes of atopic dermatitis](https://scholariq.org/papers/nomenclature-and-clinical-phenotypes-of-atopic-dermatitis/)
- [Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis](https://scholariq.org/papers/dupilumab-significantly-improves-skin-barrier-function-in-patients-with-moderate/)
- [The disease burden of pediatric patients with atopic dermatitis in Japan](https://scholariq.org/papers/the-disease-burden-of-pediatric-patients-with-atopic-dermatitis-in-japan/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Researcher university

- [Sanofi (United States)](https://scholariq.org/institutions/sanofi-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.